Approved by Global Regulatory
and Partner Audits
About Us
Company Profile
Aton Biotech is a fast-growing CDMO company which is committed to enabling new biological drugs for clients with an integrated bio-pharmaceutical platform. Our service ranges from cell line development to clinical and end-to-end CDMO commercial manufacturing services, including development of mammalian expressed monoclonal antibodies, fusion proteins, bispecific antibodies, ADC, etc.
Aton Biotech has two R&D &manufacturing sites in Shanghai. Both are equipped with the latest technology and fully compliant with the cGMP requirement of the NMPA, EMA and FDA.
-
+
-
+Molecules
(mAb, BsAb, fusion protein, ADC, etc.) -
+IND Projects
(China, USA, etc.) -
%Technology transfer success rate
-
+Tox & clinical batches
-
+Commercial batches
-
Corporate CultureMission: Enable innovation from concept to market with quality and speed
Vision: Become the CDMO of choice for the global biopharmaceutical industry
Core Value: Quality, Integrity, Efficiency, Excellence
Management Team
In addition to the industry-leading manufacturing technology platforms, Aton has established an international level biopharmaceutical R & D, production, and operation management team, with high-quality talent reserve and perfect team structure. The core management team has more than 15 years of senior management and industry experience in drug R & D, clinical, production, CMC, quality, and compliance from leading multinational pharmaceutical companies.
张文杰
董事长、执行董事兼首席执行官
张文杰先生在医药行业拥有逾25年的商业运营经验，在2019年三月份加入复宏汉霖之前，张文杰先生是美国安进公司中国区总经理，负责安进公司在中国的业务扩展并致力于帮助中国患者早日受益于安进公司的创新产品。在张文杰先生的领导下，安进成功的组建了完整的商业化团队，并在中国上市了公司的第一个产品瑞百安。
在此之前，张文杰先生担任安进公司日本及亚太区市场执行总监，负责包括中国、日本、澳大利亚、和其它亚太国家和地区的市场及业务发展。
Business Ethics
Aton Biotech takes quality and integrity as the principle. All employees strive to deal honestly, ethically, and fairly with our suppliers, customers, and competitors.